Elon Musk Explores Possible Tesla-SpaceX Merger Amid Growing AI Investments 
RBNZ Holds Interest Rates Steady but Signals More Hikes Ahead in 2026 
Morgan Stanley Names Top AI Security and Data Center Stocks for 2026 
European EV Sales Surge in April 2026 as Tesla and Chinese Automakers Gain Ground 
Asian Stocks Slip as U.S.-Iran Tensions Weigh on Markets; South Korea’s KOSPI Hits Record High 
SpaceX Starship V3 Test Flight Boosts IPO Momentum Ahead of Historic Market Debut 
Huawei Chip Breakthrough Sparks Rally in Hong Kong AI and Semiconductor Stocks 
US Stock Futures Rise as Iran Talks Ease Oil Fears Ahead of Key Inflation Data 
Boeing Wins Fraud Lawsuit Over 737 MAX Filed by LOT Polish Airlines 
NHS shakeup: if it sounds like we’ve been here before, it’s because we have 
Texas Sues Meta Over WhatsApp Encryption Claims 
Ferrari Luce: How Ferrari Evolved From Hybrid Supercars to Its First Fully Electric Vehicle 
Goldman Sachs to Pay $500M in 1MDB Shareholder Fraud Settlement 
Gold Prices Slip as Fresh U.S. Strikes on Iran Boost Dollar and Oil Markets 
PDG Explores $1 Billion Sale of China Data Center Assets 
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs 
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO 
Lotte Biologics has completed the acquisition process to take over the manufacturing facility of Bristol Myers Squibb in Syracuse, New York, for $160 million. The drug manufacturing unit of the Lotte Group confirmed the deal on Tuesday, Jan. 3.
With the addition of Bristol Myers Squibb’s plant in Lotte Biologics’ property portfolio, the fifth-largest retail-chemical company in South Korea has officially jumped into the contract manufacturing business. This acquisition also comes after the Lotte Group launched Lotte Biologics, a biological CDMO (Contract Development Manufacturing Organization), in June 2022.
As per The Korea Herald, the company actually completed the takeover of the Bristol Myers Squibb facility on Dec. 31. All of its existing manufacturing contract agreements for drug production are also included in the acquisition. It was reported that these deals are worth $220 million and deliveries are to be carried out over the next three years.
The South Korean CDMO firm also revealed its plans to invest $70 million to upgrade the manufacturing facility in Syracuse. This investment will add manufacturing lines for drug substances, antibody-drug conjugates, and other drug products.
As Lotte Biologics buys Bristol Myers Squibb's manufacturing facility, it will also be creating around 70 jobs, and they will be assigned to various roles at the plant. This will be an addition to the existing BMS workforce, which is said to be 450 in number.
“Based on the successful acquisition of the Syracuse Plant, Lotte Biologics will emerge as a global CDMO that can achieve 1.5 trillion KRW in sales, a 30% operating margin, and a corporate value of 20 trillion KRW by 2030 by providing innovative medicines to patients,” Lotte Biologics’ chief executive officer, Richard Lee, said in a press release. “We will continue to grow at a rapid pace.”
The CEO further said that his goal is to successfully establish the company as a new growth engine for the Lotte Group. Lee will work on achieving this ambition by signing partnership deals with some global pharmaceutical companies and securing other bio ventures.
